AC
CSTL icon

Apogem Capital’s Castle Biosciences CSTL Stock Holding History

Apogem Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,130
Closed -$238K – 25
2022
Q3 		$238K Hold
9,130
– – 0.24% 111
2022
Q2 		$200K Buy
+9,130
New +$212K 0.18% 139

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Apogem Capital's CSTL Position: Q4 2022 in Review

Apogem Capital sold out of Castle Biosciences (CSTL) in Q4 2022, closing a stake of 9,130 shares — an estimated $238K sold.

Apogem Capital first reported a position in CSTL in Q2 2022 and held it in 2 quarters. The position peaked at $238K in Q3 2022. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

  • Apogem Capital reported no remaining Castle Biosciences position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 9,130 Castle Biosciences shares in Q4 2022, an estimated $238K.
  • Apogem Capital first reported a position in Castle Biosciences in Q2 2022 and held it in 2 quarters.
  • Apogem Capital's Castle Biosciences position peaked at $238K in Q3 2022.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.